Isomer-Turosteride
Code | Size | Price |
---|
TAR-T71703L-1mg | 1mg | £227.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T71703L-5mg | 5mg | £416.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T71703L-10mg | 10mg | £581.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T71703L-25mg | 25mg | £863.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T71703L-50mg | 50mg | £1,163.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Documents
Further Information
Bioactivity:
Isomer-Turosteride is a novel 5 alpha-reductase inhibitor.The antiprostatic effect of Isomer-Turosteride in adult rats is associated with the inhibition of the conversion of T to DHT.Isomer-Turosteride induces a decrease in prostate DHT independent of a secondary increase in T. Isomer-Turosteride has anticancer activity and inhibits the growth of tumor cells. Turosteride has anticancer activity and inhibits the growth of tumor cells.
Translated with www.DeepL.com/Translator (free version)
Molecular Weight:
459.67
Pathway:
Metabolism|Endocrinology/Hormones
Purity:
0.9972
SMILES:
C[C@@]12[C@](CC[C@@H]2C(N(C(C)C)C(NC(C)C)=O)=O)([H])[C@@]3([H])[C@@](CC1)([H])[C@@]4([C@](N(C(CC4)=O)C)([H])CC3)C
Target:
Reductase
References
Hudak SJ, et al. Role of 5 alpha-reductase inhibitors in the management of prostate cancer. Clin Interv Aging. 2006;1(4):425-431.